DE602004026597D1 - Behandlung von alzheimer-krankheit und verwandten zuständen - Google Patents
Behandlung von alzheimer-krankheit und verwandten zuständenInfo
- Publication number
- DE602004026597D1 DE602004026597D1 DE602004026597T DE602004026597T DE602004026597D1 DE 602004026597 D1 DE602004026597 D1 DE 602004026597D1 DE 602004026597 T DE602004026597 T DE 602004026597T DE 602004026597 T DE602004026597 T DE 602004026597T DE 602004026597 D1 DE602004026597 D1 DE 602004026597D1
- Authority
- DE
- Germany
- Prior art keywords
- treatment
- alzheimer disease
- related states
- states
- alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 abstract 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/96—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0318552A GB0318552D0 (en) | 2003-08-07 | 2003-08-07 | Therapeutic treatment |
| GB0408100A GB0408100D0 (en) | 2004-04-08 | 2004-04-08 | Therapeutic agents |
| PCT/GB2004/003286 WO2005013985A1 (en) | 2003-08-07 | 2004-07-29 | Treatment for alzheimer's disease and related conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602004026597D1 true DE602004026597D1 (de) | 2010-05-27 |
Family
ID=34137751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004026597T Active DE602004026597D1 (de) | 2003-08-07 | 2004-07-29 | Behandlung von alzheimer-krankheit und verwandten zuständen |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20080153817A1 (de) |
| EP (1) | EP1656141B1 (de) |
| JP (1) | JP4769718B2 (de) |
| AT (1) | ATE464048T1 (de) |
| AU (1) | AU2004262970B2 (de) |
| CA (1) | CA2534240A1 (de) |
| DE (1) | DE602004026597D1 (de) |
| WO (1) | WO2005013985A1 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7019022B2 (en) | 2003-12-15 | 2006-03-28 | Merck Frosst Canada & Co. | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives |
| ATE384046T1 (de) * | 2004-04-02 | 2008-02-15 | Merck & Co Inc | Verfahren zur asymmetrischen hydrierung, das sich für die herstellung von cycloalkanindolderivaten eignet |
| GB0410238D0 (en) * | 2004-05-07 | 2004-06-09 | Merck Sharp & Dohme | Therapeutic agents |
| GB0522908D0 (en) * | 2005-11-10 | 2005-12-21 | Merck Sharp & Dohme | Therapeutic agents |
| EP2121633A2 (de) | 2007-02-12 | 2009-11-25 | Merck & Co., Inc. | Piperazinderivate zur behandlung von alzheimer-krankheit und verwandten leiden |
| CA2742897A1 (en) | 2008-11-06 | 2010-05-14 | Astrazeneca Ab | Modulators of amyloid beta. |
| EP2378879A4 (de) | 2008-12-16 | 2012-06-06 | Merck Sharp & Dohme | Triazolderivate für die behandlung von morbus alzheimer |
| DK3004080T3 (da) | 2013-06-04 | 2019-01-02 | Acturum Real Estate Ab | Triazolforbindelser og deres anvendelse som gamma-sekretase-modulatorer |
| JP6368776B2 (ja) | 2013-06-04 | 2018-08-01 | アクチュラム・ライフ・サイエンス・アクチエボラーグ | トリアゾール化合物およびガンマセクレターゼモジュレーターとしてのその使用 |
| NO3004079T3 (de) | 2013-06-04 | 2018-06-16 | ||
| WO2019121143A1 (en) | 2017-12-20 | 2019-06-27 | Basf Se | Substituted cyclopropyl derivatives |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5021447A (en) * | 1986-01-23 | 1991-06-04 | Merck Frosst Canada, Inc. | Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions |
| ATE61047T1 (de) * | 1986-01-23 | 1991-03-15 | Merck Frosst Canada Inc | Tetrahydrocarbazol-1-alkansaeuren. |
| US4808608A (en) * | 1986-01-23 | 1989-02-28 | Merck & Co., Inc. | Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use |
| EP0307077A1 (de) * | 1987-07-21 | 1989-03-15 | Merck Frosst Canada Inc. | Tetrahydrocarbazole zur Verbesserung der Cyclosporintherapie |
| AU1407399A (en) * | 1997-11-14 | 1999-06-07 | Eli Lilly And Company | Treatment for alzheimer's disease |
| AU4229499A (en) * | 1998-07-30 | 2000-02-21 | Warner-Lambert Company | Tricyclic heteroaromatics and their derivatives as inhibitors of matrix metalloproteinases |
| US6410583B1 (en) * | 2000-07-25 | 2002-06-25 | Merck Frosst Canada & Co. | Cyclopentanoindoles, compositions containing such compounds and methods of treatment |
| CA2357450A1 (en) * | 2000-09-29 | 2002-03-29 | Warner-Lambert Company | Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis |
| EP1349858B1 (de) * | 2000-11-02 | 2008-08-27 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Wirkstoffe für die verminderung von amyloid precursor protein und die behandlung von schwachsinn, und deren verfahren der verwendung |
| AR038136A1 (es) * | 2002-01-24 | 2004-12-29 | Merck Frosst Canada Inc | Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento |
-
2004
- 2004-07-29 JP JP2006522393A patent/JP4769718B2/ja not_active Expired - Fee Related
- 2004-07-29 CA CA002534240A patent/CA2534240A1/en not_active Abandoned
- 2004-07-29 WO PCT/GB2004/003286 patent/WO2005013985A1/en active Application Filing
- 2004-07-29 AT AT04767944T patent/ATE464048T1/de not_active IP Right Cessation
- 2004-07-29 US US10/566,844 patent/US20080153817A1/en not_active Abandoned
- 2004-07-29 EP EP04767944A patent/EP1656141B1/de active Active
- 2004-07-29 DE DE602004026597T patent/DE602004026597D1/de active Active
- 2004-07-29 AU AU2004262970A patent/AU2004262970B2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20080153817A1 (en) | 2008-06-26 |
| ATE464048T1 (de) | 2010-04-15 |
| JP4769718B2 (ja) | 2011-09-07 |
| WO2005013985A1 (en) | 2005-02-17 |
| AU2004262970B2 (en) | 2010-03-18 |
| EP1656141A1 (de) | 2006-05-17 |
| CA2534240A1 (en) | 2005-02-17 |
| AU2004262970A1 (en) | 2005-02-17 |
| JP2007501778A (ja) | 2007-02-01 |
| EP1656141B1 (de) | 2010-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE383853T1 (de) | Arylessigsäuren und verwandte verbindungen zur behandlung von alzheimer-krankheit | |
| ATE455763T1 (de) | Piperidine und verwandte verbindungen zur behandlung von alzheimer-krankheit | |
| DE602005011279D1 (de) | Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen | |
| DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| ATE380809T1 (de) | Trisubstituiertes aryl- und heteroarylderivate als stoffwechselmodulatoren und die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen | |
| DE602004016729D1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
| ATE441417T1 (de) | Benzoädüazepinderivate für die behandlung von neurologischen krankheiten | |
| ATE374196T1 (de) | Dihydrobenzodiazepin-2-on-derivative für die behandlung von neurologischen erkrankungen | |
| ATE512163T1 (de) | Verabreichung von mitteln zur behandlung von entzündungen | |
| ATE396174T1 (de) | Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten | |
| ATE410430T1 (de) | 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose | |
| TW200509892A (en) | Novel aminobenzophenone compounds | |
| ATE502642T1 (de) | Kombinationen für die behandlung von immun- entzündlichen erkrankungen | |
| ATE443704T1 (de) | Pyridopyrimidinone zur behandlung von krebserkrankungen | |
| DE602005015697D1 (de) | Te zur behandlung von alzheimer-krankheit | |
| DE60204466D1 (de) | Integrinhemmer zur behandlung von augenkrankheiten | |
| DE602004023721D1 (de) | Zusammensetzungen und methoden für die behandlung von herzerkrankungen | |
| DE602004026597D1 (de) | Behandlung von alzheimer-krankheit und verwandten zuständen | |
| EA200401319A1 (ru) | Новые гетероциклические соединения, способы их получения и фармацевтические композиции, содержащие эти соединения, и их использование в медицине | |
| ATE482706T1 (de) | Behandlung bakterieller erkrankungen der atmungsorgane durch lokale applikation von fluorchinolonen | |
| DE602007012272D1 (de) | Difluorierte piperidine zur behandlung von morbus alzheimer und verwandten leiden | |
| ATE519740T1 (de) | Tetrahydroindolderivate zur behandlung von alzheimer-krankheit | |
| DE60131968D1 (de) | PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN | |
| NO20053562L (no) | Nye aminobenzofenonforbindelser | |
| DE60318081D1 (de) | Verwendung von brimonidine zur behandlung von dementia und morbus parkinson |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |